February 18, 2025 03:44 PM Eastern Standard Time CHICAGO–(BUSINESS WIRE)–MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements…
October 28, 2024 07:00 PM Eastern Daylight Time CHICAGO–(BUSINESS WIRE)–MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements…
According to filings with the U.S. Securities and Exchange Commission, MAIA Biotechnology is raising up to $5,700,000.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Vlad Vitoc…